Last reviewed · How we verify
NCT04600388
Efficacy and Safety of Nerivio for the Acute Treatment of Menstrual Migraine
trial testing Nerivio in Menstrual Migraine in 121 participants. Completed in 10 November 2020.
1 November 2020
Quick facts
| Lead sponsor | Theranica |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 121 |
| Start date | 9 September 2020 |
| Primary completion | 1 November 2020 |
| Estimated completion | 10 November 2020 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Nerivio
Conditions studied
- Menstrual Migraine — all drugs for Menstrual Migraine →
Sponsor
Theranica — full company profile →
Who can join
Adults 18 to 55, female only, with Menstrual Migraine. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Post-marketing, retrospective, observational survey study. Users (menstruating women only) of Nerivio who have used Nerivio at least 4 times between October 2019 and December 2020 will be contacted by email and/or through an app notification and will be asked to complete a 5-minute online anonymous survey assessing satisfaction, effectiveness, and safety. Eligible users will sign an informed consent form (the consent language will appear as the first page of the survey, and participants will click either "agree" or "disagree" to the consent statement; those who click "agree" will proceed to the survey, those who click "disagree" will be brought to an exit page) and complete a survey asking about their satisfaction with Nerivio and the effectiveness and safety of the device for acute treatment of menstrual migraine. During the survey, participants will be screened to verify that they have menstrual migraine (self-reported) and have used Nerivio to treat menstrual migraines.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Remote Electrical Neuromodulation (REN) for the Acute Treatment of Menstrual Migraine: a Retrospective Survey Study of Effectiveness and Tolerability.
Nierenburg H, Rabany L, Lin T, Sharon R, et al · · 2021 · cited 8× · PMID 34138449 · DOI 10.1007/s40122-021-00276-7
Verify or expand the search:
- PubMed search for NCT04600388
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Nerivio
Trials testing the same drug.
- NCT06976723 — Nerivio Efficacy by Time of Treatment Onset · Phase 4 · completed
- NCT06738056 — Nerivio Long-term Usage in Patients With Migraine · completed
- NCT06180577 — A Survey Study to Assess the Accessibility of the Nerivio Device At School · completed
- NCT06138756 — Acute Treatment of Migraine in Pre-Adolescents: Real-World Analysis of Remote Electrical Neuromodulation (REN) · completed
- NCT05940870 — A Prospective Post-marketing Observational Study Assessing the Safety and Efficacy of Nerivio for Migraine Prevention. · completed
Other recruiting trials for Menstrual Migraine
Currently open trials in the same condition.
- NCT06641466 — A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual · Phase 3 · recruiting
- NCT06659120 — Fremanezumab for the Prevention of Menstrually-related Migraine Attacks · recruiting
Other Theranica trials
Trials by the same sponsor.
- NCT05523310 — Observational Study to Assess Migraine Prediction Tool · suspended
- NCT07487701 — Migraine Prevention With the Remote Electrical Neuromodulation (REN) Wearable: A Real-world Evidence Study · NA · active not recruiting
- NCT07336420 — Treatment Patterns Among US Veterans Using Remote Electrical Neuromodulation (REN) for Migraine Treatment · Phase 4 · completed
- NCT07336056 — Nerivio Efficacy Under High-Frequency Use · Phase 4 · active not recruiting
- NCT06976723 — Nerivio Efficacy by Time of Treatment Onset · Phase 4 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04600388 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Theranica
- Last refreshed: 4 December 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04600388.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing